Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
FATE Stock Forecast 2026-2027
$1.08
Current Price
$117.66M
Market Cap
Buy 6
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to FATE Price Targets
+640.7%
To High Target of $8.00
+363.0%
To Median Target of $5.00
+85.2%
To Low Target of $2.00
FATE Price Momentum
+1.9%
1 Week Change
-3.6%
1 Month Change
-18.2%
1 Year Change
+10.2%
Year-to-Date Change
-44.3%
From 52W High of $1.94
+63.6%
From 52W Low of $0.66
📊 TOP ANALYST CALLS
Did FATE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Fate Therapeutics is one of their latest high-conviction picks.
Latest FATE Stock Price Targets & Analyst Predictions
Based on our analysis of 27 Wall Street analysts, FATE has a neutral consensus with a median price target of $5.00 (ranging from $2.00 to $8.00). The overall analyst rating is N/A (N/A/10). Currently trading at $1.08, the median forecast implies a 363.0% upside. This outlook is supported by 6 Buy, 6 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Mara Goldstein at Mizuho, projecting a 640.7% upside. Conversely, the most conservative target is provided by Peter Lawson at Barclays, suggesting a 85.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FATE Analyst Ratings
6
Buy
6
Hold
0
Sell
FATE Price Target Range
Low
$2.00
Average
$5.00
High
$8.00
Current: $1.08
Latest FATE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FATE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 31, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Upgrade | $5.00 |
| Oct 27, 2025 | Needham | Gil Blum | Hold | Reiterates | $N/A |
| Oct 27, 2025 | Wedbush | David Nierengarten | Outperform | Upgrade | $7.00 |
| Aug 13, 2025 | Wells Fargo | Yanan Zhu | Equal-Weight | Maintains | $2.50 |
| Jun 12, 2025 | Needham | Gil Blum | Hold | Reiterates | $N/A |
| May 14, 2025 | Needham | Gil Blum | Hold | Reiterates | $N/A |
| May 14, 2025 | Baird | Jack Allen | Neutral | Maintains | $4.00 |
| May 14, 2025 | Barclays | Peter Lawson | Overweight | Maintains | $2.00 |
| Mar 6, 2025 | Wedbush | David Nierengarten | Neutral | Reiterates | $5.00 |
| Mar 6, 2025 | Needham | Gil Blum | Hold | Reiterates | $N/A |
| Mar 6, 2025 | Wells Fargo | Yanan Zhu | Equal-Weight | Maintains | $4.00 |
| Mar 6, 2025 | Stifel | Benjamin Burnett | Hold | Maintains | $3.00 |
| Nov 19, 2024 | Needham | Gil Blum | Hold | Reiterates | $N/A |
| Nov 13, 2024 | Needham | Gil Blum | Hold | Reiterates | $N/A |
| Aug 22, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Reiterates | $5.00 |
| Aug 14, 2024 | Needham | Gil Blum | Hold | Reiterates | $N/A |
| Jun 17, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Upgrade | $6.00 |
| May 16, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Neutral | Maintains | $5.00 |
| May 10, 2024 | BMO Capital | Etzer Darout | Market Perform | Maintains | $6.00 |
| May 10, 2024 | Piper Sandler | Edward Tenthoff | Neutral | Maintains | $4.00 |
Fate Therapeutics Inc. (FATE) Competitors
The following stocks are similar to Fate Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
FATE
Fate Therapeutics
mkt cap
121.12M
Fate Therapeutics Inc. (FATE) Financial Data
Fate Therapeutics Inc. has a market capitalization of $117.66M with a P/E ratio of -0.6x. The company generates $7.14M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -43.4% quarter-over-quarter, while maintaining an operating margin of -1,995.1% and return on equity of -52.3%.
Valuation Metrics
Market Cap
$117.66M
Enterprise Value
$-12,748,051
P/E Ratio
-0.6x
PEG Ratio
0.0x
Price/Sales
16.7x
Growth & Margins
Revenue Growth (YoY)
-43.4%
Gross Margin
N/A
Operating Margin
-1,995.1%
Net Margin
0.0%
EPS Growth
-43.4%
Financial Health
Cash/Price Ratio
+173.0%
Current Ratio
7.9x
Debt/Equity
33.9x
ROE
-52.3%
ROA
-23.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Fate Therapeutics Inc. (FATE) Business Model
About Fate Therapeutics Inc.
What They Do
Develops programmed cellular immunotherapies for cancer.
Business Model
The company creates off-the-shelf cellular therapy candidates using pluripotent stem cells and proprietary cell programming technology. By focusing on scalable and consistent cell-based therapies, Fate Therapeutics aims to generate revenue through partnerships and collaborations with other industry leaders and research institutions, advancing its innovative product pipeline.
Additional Information
Founded in the early 2000s and based in San Diego, California, Fate Therapeutics is strategically positioned to tackle critical unmet medical needs in oncology and immunology. Its commitment to innovation highlights the growing significance of cellular therapies in modern medicine, potentially benefiting patients globally.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
181
CEO
Dr. Bahram Valamehr M.B.A., Ph.D.
Country
United States
IPO Year
2013
Website
www.fatetherapeutics.comFate Therapeutics Inc. (FATE) Latest News & Analysis
Latest News
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
9 days ago
Quick Summary
Fate Therapeutics granted stock options for 48,000 shares and RSUs for 79,400 shares to new non-executive employees, with vesting over four years, compliant with Nasdaq rules.
Why It Matters
The grant of stock options and RSUs signals Fate Therapeutics' commitment to attracting talent, which can enhance innovation and growth, potentially impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fate Therapeutics (NASDAQ: FATE) will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, with management participating in a fireside chat and panel discussion.
Why It Matters
Fate Therapeutics' participation in a prominent healthcare conference highlights its commitment to innovation and potential breakthroughs, which can influence investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
UK and EU authorities have authorized the activation of ex-US clinical trial sites for FT819, a CAR T-cell product aimed at improving patient accessibility with reduced conditioning.
Why It Matters
Authorization for FT819 clinical trials expands market potential and accessibility, potentially boosting revenues and investor confidence in the company’s growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fate Therapeutics (FATE) reported a Q3 loss of $0.27 per share, better than the estimated loss of $0.29 and an improvement from a loss of $0.40 per share a year prior.
Why It Matters
Fate Therapeutics reported a smaller-than-expected quarterly loss, indicating improved performance. This may boost investor confidence and positively influence stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
2 months ago
Quick Summary
Fate Therapeutics (FATE) lacks the necessary factors for a potential earnings beat in its upcoming report, indicating lower expectations for performance.
Why It Matters
Fate Therapeutics may underperform in its earnings report, signaling potential declines in stock value, impacting investor sentiment and decisions.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Relay, Fate, and Verastem are making progress with their cancer therapies, enhancing their pipelines in a dynamic oncology market.
Why It Matters
Advancements in cancer therapies by Relay, Fate, and Verastem enhance their market positions, potentially increasing future revenues and attracting investor interest in the oncology sector.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About FATE Stock
What is Fate Therapeutics Inc.'s (FATE) stock forecast for 2026?
Based on our analysis of 27 Wall Street analysts, Fate Therapeutics Inc. (FATE) has a median price target of $5.00. The highest price target is $8.00 and the lowest is $2.00.
Is FATE stock a good investment in 2026?
According to current analyst ratings, FATE has 6 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.08. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FATE stock?
Wall Street analysts predict FATE stock could reach $5.00 in the next 12 months. This represents a 363.0% increase from the current price of $1.08. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fate Therapeutics Inc.'s business model?
The company creates off-the-shelf cellular therapy candidates using pluripotent stem cells and proprietary cell programming technology. By focusing on scalable and consistent cell-based therapies, Fate Therapeutics aims to generate revenue through partnerships and collaborations with other industry leaders and research institutions, advancing its innovative product pipeline.
What is the highest forecasted price for FATE Fate Therapeutics Inc.?
The highest price target for FATE is $8.00 from Mara Goldstein at Mizuho, which represents a 640.7% increase from the current price of $1.08.
What is the lowest forecasted price for FATE Fate Therapeutics Inc.?
The lowest price target for FATE is $2.00 from Peter Lawson at Barclays, which represents a 85.2% increase from the current price of $1.08.
What is the overall FATE consensus from analysts for Fate Therapeutics Inc.?
The overall analyst consensus for FATE is neutral. Out of 27 Wall Street analysts, 6 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are FATE stock price projections?
Stock price projections, including those for Fate Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 2:55 AM UTC